Best Peptides for Muscle Growth

ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) fused to a human IgG1 Fc domain. It functions as a soluble decoy receptor or 'myostatin trap,' intercepting myostatin and other TGF-β superfamily ligands before they can bind to muscle cells and inhibit growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy, it produced remarkable muscle-building effects in early clinical trials before development was paused due to minor vascular side effects.

CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF, is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile growth hormone release from the anterior pituitary. It is the most widely used GHRH analog in peptide therapy, prized for producing physiological GH pulses that mimic the body's natural secretory pattern. Its shorter half-life (~30 minutes vs. 8 days for the DAC version) allows discrete GH pulses rather than sustained elevation, which many consider more physiological and safer for long-term use. Almost always paired with a GHRP — typically Ipamorelin — for dramatically amplified GH output.

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analog that uses a maleimidopropionic acid modification to covalently bind to circulating serum albumin after injection, extending its half-life to approximately 8 days. Unlike the no-DAC version which produces discrete GH pulses, CJC-1295 with DAC creates sustained, continuous GHRH receptor stimulation, resulting in chronically elevated GH and IGF-1 levels. This produces consistently high IGF-1 output with less frequent dosing (once or twice per week), but at the cost of natural pulsatility — a trade-off that divides the peptide community.

GHRP-2 (Growth Hormone Releasing Peptide-2, pralmorelin) is a synthetic hexapeptide that potently stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the anterior pituitary. It is one of the most potent GHRPs available, producing robust GH pulses comparable to GHRH stimulation tests. GHRP-2 also stimulates appetite, modulates cortisol and prolactin, and has demonstrated cytoprotective properties.

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and one of the original growth hormone secretagogues. It stimulates GH release via the ghrelin receptor and is known for producing the most pronounced hunger response among GHRPs. It also demonstrates gastroprotective and cardioprotective properties independent of GH release.

Hexarelin is a synthetic hexapeptide growth hormone secretagogue and one of the most potent GHRPs, producing the largest GH release of any peptide in its class. It acts through the ghrelin receptor and also exhibits significant cardioprotective properties independent of GH release. However, it is prone to desensitization with continuous use.

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), increasing its bioavailability and half-life from ~15 minutes to 20–30 hours. It is the most potent anabolic peptide available for direct tissue growth.

Ipamorelin is a selective growth hormone secretagogue pentapeptide that stimulates GH release with remarkable specificity — it activates the ghrelin receptor without significantly affecting cortisol, prolactin, or appetite. This selectivity profile makes it the 'cleanest' GHRP and the most widely used growth hormone peptide for anti-aging, body composition, sleep enhancement, and recovery. Developed by Novo Nordisk in the 1990s, it has become the foundational GH peptide in clinical and self-directed protocols worldwide.

The Ipamorelin/CJC-1295 blend combines two complementary GH-releasing peptides in a single vial: Ipamorelin (a GHRP acting on the ghrelin receptor) and CJC-1295 without DAC (a GHRH analog acting on the GHRH receptor). This combination is the gold standard for GH optimization, producing synergistic GH pulses 3–5 times greater than either peptide alone.

The Ipamorelin/Tesamorelin blend combines Ipamorelin (GHRP) with Tesamorelin (a GHRH analog with FDA-approved status for visceral adiposity reduction). This blend is specifically popular for body composition optimization, particularly visceral fat reduction, leveraging the GHRH+GHRP synergy with Tesamorelin's demonstrated fat-targeting properties.

PEG-MGF (PEGylated Mechano Growth Factor) is a PEGylated version of the MGF splice variant of IGF-1 (IGF-1Ec in humans). The addition of polyethylene glycol (PEG) extends its half-life from minutes to hours, enabling systemic administration. MGF is naturally produced in response to mechanical stress on muscle tissue and plays a critical role in activating satellite cells for muscle repair and growth.

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the native 44-amino acid GHRH sequence. It is the shortest fragment of GHRH that retains full biological activity at the pituitary. Sermorelin was FDA-approved for the diagnosis and treatment of growth hormone deficiency in children and has become one of the most widely used growth hormone secretagogues in anti-aging and peptide therapy. Unlike exogenous GH, sermorelin stimulates natural pulsatile GH release, preserving the body's feedback mechanisms.

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus that enhances receptor binding and enzymatic stability. It is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it one of the few peptides with specific FDA approval for a body composition indication. Tesamorelin is the most potent GHRH analog in clinical use and has shown remarkable specificity for visceral fat reduction.